Nektar Therapeutics Receives H.C. Wainwright Price Target, Reports Phase 2b Trial Data
Nektar Therapeutics (NASDAQ: NKTR) received a $135 price target from H.C. Wainwright on December 16, 2025. This indicates a potential increase of approximately 164%. The biopharmaceutical company also recently announced topline results from its Phase 2b REZOLVE-AA trial for rezpegaldesleukin.
When the target was set, NKTR shares were priced at $51.17. The stock is currently trading at $49.21, reflecting a daily decrease of $4.09 or 7.67%. During current trading, the stock has fluctuated between a low of $45.25 and a high of $52.29.
The Phase 2b REZOLVE-AA trial evaluated rezpegaldesleukin for severe-to-very-severe alopecia areata, involving 92 patients over 36 weeks. Both dosage arms demonstrated more than double the reduction in the Severity of Alopecia Tool (SALT) score compared to placebo. While initially missing its primary endpoint, the trial achieved statistical significance after excluding certain patients.
Nektar Therapeutics focuses on developing innovative medicines for autoimmune diseases, oncology, and pain management. The company has a market capitalization of approximately $1 billion, with a trading volume of 4,275,313 shares. Over the past year, NKTR shares have traded between a high of $66.92 and a low of $6.45.
- Nektar Therapeutics History, Mission, Ownership
- Nektar Therapeutics Mission, Vision
- Nektar Therapeutics Financial Health
- Nektar Therapeutics Investor Profile
Nektar Therapeutics (NKTR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.